Monday, March 27, 2023
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Biodetection

General Atomics Awarded DARPA Contract for Portable Diagnostic Device

by Global Biodefense Staff
February 15, 2018
Notable CBRN Contracts

General Atomics Electromagnetic Systems (GA-EMS) has been awarded a contract from the Defense Advanced Research Projects Agency (DARPA) to develop a next generation Portable Diagnostic Platform for personnel to quickly self-perform testing for an array of infectious diseases in the field.

Over the 12-month contract period, GA-EMS will develop a verification prototype device and related assay cards for point-of-use molecular diagnostics testing. The initial contract is valued at $1,894,258.

GA-EMS will develop a next generation Portable Diagnostic Platform with unique sensor technology and customizable, single-use disposable cartridges capable of lab-quality molecular diagnostics. A small fluid sample is inserted into a cartridge containing a molecular sensor chip and various reagents that will react when they come into contact with certain pathogens. Testing occurs when the cartridge is inserted into the Portable Diagnostic Platform device, which interacts with the cartridge to prepare and analyze the sample. An easy to read positive or negative test result is then displayed in less than one hour.

“This is truly breakthrough technology, and one that GA-EMS is uniquely positioned to advance into the next development and testing phase,” noted Rolf Ziesing, vice president of Programs at GA-EMS. “We recently expanded our operations to address the complexities of designing and manufacturing ruggedized microelectronics, advanced sensors, and signal processing technologies for field-deployable systems. This new contract provides us with another opportunity to work with DARPA to develop, test and manufacture a critical technology that has the potential to directly impact our national security, and the welfare and safety of our warfighters and field personnel.”

General Atomics Electromagnetic Systems Group announced on Jan 25, 2018 the acquisition of Toronto-based Xagenic Inc., a molecular diagnostic systems company.

The acquisition supported the organization’s growth initiatives in microelectronics, advanced sensors and signal processing technologies for defense applications.

Xagenic developed a diagnostic system which uses a unique, customizable cartridge containing a proprietary sensor chip to enable rapid, lab-quality molecular diagnostics for disease detection at the point of service. The diagnostic technology is completely automated within a single-use disposable cartridge and involves nanostructured microelectrode sensors allowing direct electrochemical analysis of the prepared sample on the cartridge.

Tags: AwardsDARPAPOC DiagnosticsRuggedizedSelect Agents

Related Posts

Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA
Funding News

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
small glass vials on an assembly line await filling of vaccine solution
Industry News

Sabin Vaccine Institute to Advance Ebola Sudan and Marburg Vaccines with New BARDA Funding

January 12, 2023
two soldiers are in head-to-toe hazmat suits with respirator masks while tending to a mannikin on a stretcher
CBRNE

Protection from Biothreats: DOD to Modernize Medical Countermeasures Development

January 10, 2023
DoD Awards ENA Respiratory $4.38M for Broad-Spectrum Antiviral Development
Industry News

DoD Awards ENA Respiratory $4.38M for Broad-Spectrum Antiviral Development

January 10, 2023
Load More

Latest News

Biodefense Headlines – 26 March 2023

March 26, 2023
Biodefense Headlines – 12 March 2023

Biodefense Headlines – 12 March 2023

March 12, 2023
Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

January 25, 2023

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC